New method to combat drug resistance in skin cancer discovered

the ONA take:

Scientists at the Cancer Research UK Manchester Institute have found that MLK enzymes can be responsible for reactivating the BRAF pathway, even in the presence of vemurafenib, which allows melanoma to spread. Blocking these enzymes could provide a means to lower resistance to vemurafenib and aid future development of drugs designed to overcome vemurafenib resistance in melanoma patients.

New method to combat drug resistance in skin cancer discovered
New method to combat drug resistance in skin cancer discovered
Rapid resistance to vemurafenib—a treatment for a type of advanced melanoma, the deadliest form of skin cancer—could be prevented by blocking a druggable family of proteins, according to research. Scientists have revealed the MLK family of four enzymes 'undoes' the tumour-shrinking effects of vemurafenib.
READ FULL ARTICLE From Science Daily
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs